AI assistant
AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2021
Aug 5, 2021
31580_dirs_2021-08-05_97d65075-96ba-41c0-99b1-b776521d3df6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK: 0001439222
Period of Report: 2021-08-01
Reporting Person: Washburn Theodore James Jr. (Principal Accounting Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common stock | 2515 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock options (right to buy) | $51.2 | 2027-04-30 | Common stock (5000.0) | Direct | |
| Stock options (right to buy) | $77.7 | 2028-02-16 | Common stock (2022.0) | Direct | |
| Stock options (right to buy) | $58.86 | 2029-02-22 | Common stock (2000.0) | Direct | |
| Stock options (right to buy) | $51.51 | 2030-02-14 | Common stock (540.0) | Direct | |
| Stock options (right to buy) | $56.68 | 2031-02-10 | Common stock (1165.0) | Direct | |
| Restricted stock units | $ | Common stock (167.0) | Direct | ||
| Restricted stock units | $ | Common stock (720.0) | Direct | ||
| Restricted stock units | $ | Common stock (2331.0) | Direct | ||
| Restricted stock units | $ | Common stock (4150.0) | Direct |
Footnotes
F1: This option was granted on May 1, 2017. The shares underlying this option are fully vested.
F2: This option was granted on February 16, 2018. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F3: This option was granted on February 22, 2019. The shares underlying this option vest as to 25% of the underlying shares on February 22, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F4: This option was granted on February 14, 2020. The shares underlying this option vest as to 25% of the underlying shares on February 14, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F5: This option was granted on February 10, 2021. The shares underlying this option vest as to 25% of the underlying shares on February 10, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F6: The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments.
F7: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
F8: The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments.
F9: The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments.
F10: The restricted stock units were granted on August 1, 2021. The shares underlying the stock units will vest in full on August 1, 2023.